Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7651499 | 0.83 | MPO (0.41) | MPOADORA2ADRD2DRD1JAK2 | |
| SCHEMBL2663368 | 0.83 | MPO (0.41) | MPOADORA2ADRD2DRD1JAK2 | |
| SCHEMBL3288378 | 0.83 | MPO (0.44) | MPOADORA2ADRD2DRD1JAK2 | |
| SCHEMBL34463082 | 0.80 | MPO (0.43) | MPOADORA2ADRD2DRD1AKT1 | |
| SCHEMBL5330644 | 0.80 | MPO (0.40) | MPOADORA2ADRD2DRD1JAK2 | |
| SCHEMBL34462978 | 0.80 | MPO (0.43) | MPOADORA2ADRD2DRD1AKT1 | |
| SCHEMBL23835067 | 0.79 | MPO (0.39) | MPOADORA2ADRD2DRD1JAK2 | |
| SCHEMBL5323473 | 0.78 | RORC (0.44) | MPOADORA2AFFAR4RORCCTNNB1 | |
| SCHEMBL8886606 | 0.76 | ADORA2A (0.42) | MPOADORA2ADRD2DRD1FFAR4 | |
| SCHEMBL978248 | 0.76 | MPO (0.33) | MPOADORA2ADRD2FFAR4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351582-B2 | Aurora kinase inhibitors and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2025-07-08 | — | — | US | disclosed |
| EP-4001276-B1 | AURORA KINASE INHIBITOR AND USE THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2025-06-25 | — | — | EP | disclosed |
| US-12180197-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4304712-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-114072400-B | Aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20220306614-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022192430-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4001276-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001276-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| CN-114072400-A | Aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-0291799-B1 | DIOXYALKYLENEARYL-DIHYDROPYRIDINES AND THEIR INTERMEDIARY COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
| US-4886816-A | CARDIOTONIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-12-12 | — | — | US | disclosed |
| EP-0291799-A2 | Dioxyalkylenearyl-dihydropyridines and their intermediary compounds, process for their preparation and their use | BAYER AG (DE) | 1988-11-23 | — | — | EP | disclosed |
| US-4596880-A | Pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-24 | — | — | US | disclosed |
| EP-0006978-B1 | BENZYL ESTERS WITH FLUORINATED ETHER AND/OR THIOETHER GROUPS, THEIR PREPARATIONS AND THEIR USE AS INSECTICIDES; INTERMEDIATE PRODUCTS AND THEIR PREPARATIONS | BAYER AG (DE) | 1986-01-29 | — | — | EP | disclosed |
| EP-0041131-B1 | PREPARATION OF FLUORO-SUBSTITUTED BENZODIOXOLES AND BENZODIOXANES | BAYER AG (DE) | 1984-06-13 | — | — | EP | disclosed |
| US-4438275-A | 2,2-DIFLUORO-BENZODIOXOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-20 | — | — | US | disclosed |
| US-4310540-A | PYRETHROID-LIKE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | disclosed |
| EP-0041131-A2 | Preparation of fluoro-substituted benzodioxoles and benzodioxanes | BAYER AG (DE) | 1981-12-09 | — | — | EP | disclosed |
| EP-0006978-A2 | Benzyl esters with fluorinated ether and/or thioether groups, their preparations and their use as insecticides; intermediate products and their preparations | BAYER AG (DE) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306614-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MPO 2207/4885ADORA2A 490/4885DRD2 4122/4885 |
| US-12180197-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MPO 2207/4885ADORA2A 490/4885DRD2 4122/4885 |
| US-12351582-B2 | Aurora kinase inhibitors and uses thereof | AURKA, AURKC, AURKB | MPO 4822/4885ADORA2A 3723/4885DRD2 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.